Literature DB >> 19079265

miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42.

Seong-Yeon Park1, Jung Hyun Lee, Minju Ha, Jin-Wu Nam, V Narry Kim.   

Abstract

The tumor suppressor p53 is central to many cellular stress responses. Although numerous protein factors that control p53 have been identified, the role of microRNAs (miRNAs) in regulating p53 remains unexplored. In a screen for miRNAs that modulate p53 activity, we find that miR-29 family members (miR-29a, miR-29b and miR-29c) upregulate p53 levels and induce apoptosis in a p53-dependent manner. We further find that miR-29 family members directly suppress p85 alpha (the regulatory subunit of PI3 kinase) and CDC42 (a Rho family GTPase), both of which negatively regulate p53. Our findings provide new insights into the role of miRNAs in the p53 pathway.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19079265     DOI: 10.1038/nsmb.1533

Source DB:  PubMed          Journal:  Nat Struct Mol Biol        ISSN: 1545-9985            Impact factor:   15.369


  39 in total

Review 1.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

2.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

Review 3.  P53 and prognosis: new insights and further complexity.

Authors:  Karen H Vousden; Carol Prives
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

4.  RAS is regulated by the let-7 microRNA family.

Authors:  Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal:  Cell       Date:  2005-03-11       Impact factor: 41.582

5.  The tumor suppressor microRNA let-7 represses the HMGA2 oncogene.

Authors:  Yong Sun Lee; Anindya Dutta
Journal:  Genes Dev       Date:  2007-04-16       Impact factor: 11.361

6.  c-Myc-regulated microRNAs modulate E2F1 expression.

Authors:  Kathryn A O'Donnell; Erik A Wentzel; Karen I Zeller; Chi V Dang; Joshua T Mendell
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

Authors:  Valery Tarasov; Peter Jung; Berlinda Verdoodt; Dmitri Lodygin; Alexey Epanchintsev; Antje Menssen; Gunter Meister; Heiko Hermeking
Journal:  Cell Cycle       Date:  2007-05-11       Impact factor: 4.534

9.  NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma.

Authors:  Huating Wang; Ramiro Garzon; Hao Sun; Katherine J Ladner; Ravi Singh; Jason Dahlman; Alfred Cheng; Brett M Hall; Stephen J Qualman; Dawn S Chandler; Carlo M Croce; Denis C Guttridge
Journal:  Cancer Cell       Date:  2008-11-04       Impact factor: 31.743

Review 10.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.

Authors:  Lindsey D Mayo; David B Donner
Journal:  Trends Biochem Sci       Date:  2002-09       Impact factor: 13.807

View more
  298 in total

Review 1.  MicroRNAs, wild-type and mutant p53: more questions than answers.

Authors:  Matthew Jones; Ashish Lal
Journal:  RNA Biol       Date:  2012-06-01       Impact factor: 4.652

2.  Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.

Authors:  Li Li Lin; Wei Wang; ZhaoYang Hu; Li Wen Wang; Jing Chang; HanGuang Qian
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

Review 3.  The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury.

Authors:  Alison J Kriegel; Yong Liu; Yi Fang; Xiaoqiang Ding; Mingyu Liang
Journal:  Physiol Genomics       Date:  2012-01-03       Impact factor: 3.107

4.  Circulating hepatitis B surface antigen particles carry hepatocellular microRNAs.

Authors:  Luisa Novellino; Riccardo L Rossi; Ferruccio Bonino; Daniela Cavallone; Sergio Abrignani; Massimiliano Pagani; Maurizia R Brunetto
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

5.  EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency.

Authors:  Kasandra J Riley; Gabrielle S Rabinowitz; Therese A Yario; Joseph M Luna; Robert B Darnell; Joan A Steitz
Journal:  EMBO J       Date:  2012-03-30       Impact factor: 11.598

6.  miR-221 is required for endothelial tip cell behaviors during vascular development.

Authors:  Stefania Nicoli; Carl-Philipp Knyphausen; Lihua J Zhu; Abirami Lakshmanan; Nathan D Lawson
Journal:  Dev Cell       Date:  2012-02-14       Impact factor: 12.270

7.  Temporal microRNA expression during in vitro myogenic progenitor cell proliferation and differentiation: regulation of proliferation by miR-682.

Authors:  Yongxin Chen; Jonathan Gelfond; Linda M McManus; Paula K Shireman
Journal:  Physiol Genomics       Date:  2010-09-14       Impact factor: 3.107

Review 8.  The microRNA networks of TGFβ signaling in cancer.

Authors:  V P Sivadas; S Kannan
Journal:  Tumour Biol       Date:  2013-12-10

Review 9.  Learning the molecular mechanisms of the reprogramming factors: let's start from microRNAs.

Authors:  Chao-Shun Yang; Tariq M Rana
Journal:  Mol Biosyst       Date:  2012-10-05

Review 10.  MicroRNA control of vascular endothelial growth factor signaling output during vascular development.

Authors:  Lan T H Dang; Nathan D Lawson; Jason E Fish
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.